NEWS
AND EVENTS

The First Low-Dose Hormone-Free Intra-Uterine Device (IUD) in the U.S. in Over 40 Years

February 25, 2025

Sebela Women's Health Announces Publication of Phase 3 Pivotal Study Results for the Investigational Copper 175 mm² Intrauterine Device (IUD) in Contraception

January 24, 2025

Sebela Women’s Health Announces Further Positive Data from the Pivotal Phase 3 Study of the Investigational Copper 175 mm² Intra-Uterine Device (IUD)

October 31, 2023

FDA Approves Sebela Pharmaceuticals’ SUFLAVE™: A New Colonoscopy Preparation that Tastes Similar to a Sports Drink

June 22, 2023

Sebela Women’s Health Presents Positive Phase 3 Data for its Investigational, Next-Generation, Non-Hormonal, Low-Dose Copper Intrauterine Device (IUD)

May 18, 2023

Large-Scale, Parallel-Track Survey Focused on Women’s Health Shows Discrepancies Between Patient Preferences and Healthcare Professional Perceptions of Factors Influencing Contraceptive Use in the United States

May 16, 2023

Sebela Pharmaceuticals Announces New Division Named Sebela Women's Health

November 15, 2022

Sebela Pharmaceuticals Appoints Victor Parker as Chief Commercial Officer

October 24, 2022

Sebela Pharmaceuticals Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada

October 19, 2022

Sebela Pharmaceuticals Announces U.S. Launch of SUTAB^® Tablets, An Alternative to Liquid Colonoscopy Preparation

January 5, 2021

Sebela Pharmaceuticals acquires U.S. drug firm Braintree Laboratories

May 12, 2018